The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor

[1]  J. Blay,et al.  Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. , 2020, European journal of cancer.

[2]  C. Antonescu,et al.  Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors , 2018, Cancer Immunology Research.

[3]  C. Antonescu,et al.  Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor , 2017, Proceedings of the National Academy of Sciences.

[4]  C. Antonescu,et al.  PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors , 2016, Clinical Cancer Research.

[5]  Eric C. Sorenson,et al.  Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. , 2015, Cancer research.

[6]  M. Odenthal,et al.  Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy , 2015, BMC Cancer.

[7]  V. Satagopam,et al.  Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics , 2015, Cell Communication and Signaling.

[8]  C. Antonescu,et al.  Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. , 2015, Cancer discovery.

[9]  Eric C. Sorenson,et al.  Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor , 2014, Clinical Cancer Research.

[10]  A Chaix,et al.  KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570 , 2014, Oncogene.

[11]  Lu Jin,et al.  Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants , 2014, Cancer science.

[12]  Eric C. Sorenson,et al.  KIT oncogene inhibition drives intratumoral macrophage M2 polarization , 2013, The Journal of experimental medicine.

[13]  S. Lowe,et al.  Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A , 2012, Leukemia.

[14]  C. Antonescu,et al.  Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor , 2012, Proceedings of the National Academy of Sciences.

[15]  H. Joensuu,et al.  The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. , 2012, Annual Review of Medicine.

[16]  Eric C. Sorenson,et al.  Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido , 2012 .

[17]  Laurent Gros,et al.  Mechanisms of STAT Protein Activation by Oncogenic KIT Mutants in Neoplastic Mast Cells* , 2010, The Journal of Biological Chemistry.

[18]  C. Antonescu,et al.  ETV1 is a lineage-specific survival factor in GIST and cooperates with KIT in oncogenesis , 2010, Nature.

[19]  Narasimhan P. Agaram,et al.  Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance , 2009, Clinical Cancer Research.

[20]  M. Mann,et al.  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. , 2009, Molecular cell.

[21]  Yan Zhang,et al.  KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients , 2009, Proceedings of the National Academy of Sciences.

[22]  S. Ward,et al.  Changes in the structure and function of ICC networks in ICC hyperplasia and gastrointestinal stromal tumors. , 2009, Gastroenterology.

[23]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Antonescu,et al.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Lorincz,et al.  Progenitors of interstitial cells of cajal in the postnatal murine stomach. , 2008, Gastroenterology.

[26]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Fletcher,et al.  KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance , 2007, Oncogene.

[28]  W. Pao,et al.  Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors , 2007, PloS one.

[29]  A. B. Lyons,et al.  Resistance to c-KIT kinase inhibitors conferred by V654A mutation , 2007, Molecular Cancer Therapeutics.

[30]  S. Ward,et al.  Kit signaling is essential for development and maintenance of interstitial cells of Cajal and electrical rhythmicity in the embryonic gastrointestinal tract , 2007, Developmental dynamics : an official publication of the American Association of Anatomists.

[31]  M. Ferrone,et al.  Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients , 2006, Oncogene.

[32]  P. Marynen,et al.  Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate , 2006, Clinical Cancer Research.

[33]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[34]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[35]  T. Graf,et al.  Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing , 2004, Development.

[36]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[37]  C. Ball,et al.  The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. , 2004, The American journal of pathology.

[38]  J. Fletcher,et al.  Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs) , 2004, Oncogene.

[39]  R. Rottapel,et al.  Signal transduction by several KIT juxtamembrane domain mutations , 2003, Oncogene.

[40]  C. Antonescu,et al.  Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Charnock-Jones,et al.  vavCre Transgenic mice: A tool for mutagenesis in hematopoietic and endothelial lineages , 2002, Genesis.

[42]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[43]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[44]  M. Klüppel,et al.  Developmental origin and kit‐dependent development of the interstitial cells of cajal in the mammalian small intestine , 1998, Developmental dynamics : an official publication of the American Association of Anatomists.

[45]  P. Lansdorp,et al.  Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells. , 1996, Experimental hematology.

[46]  P. Besmer,et al.  Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice , 1994, The Journal of experimental medicine.

[47]  P. Swiatek,et al.  Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20. , 1993, Genes & development.

[48]  K. Nocka,et al.  Molecular bases of dominant negative and loss of function mutations at the murine c‐kit/white spotting locus: W37, Wv, W41 and W. , 1990, The EMBO journal.

[49]  S. Ward,et al.  Development of c-Kit-positive cells and the onset of electrical rhythmicity in murine small intestine. , 1997, Gastroenterology.

[50]  A. Carmagnola.  [The mast cell]. , 1988, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.